Effect of USP Induction Ports, Glass Sampling Apparatus, and Inhaler Device Resistance on Aerodynamic Patterns of Fluticasone Propionate–Loaded Engineered Mannitol Microparticles
- 23 May 2019
- journal article
- research article
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 20 (5) , 197
Abstract
The present investigation is to study the effect of two different induction ports (IP), i.e., USP IP and USP-modified IP equipped with andersen cascade impactor on in vitro aerodynamic performance along with the impact of USP-modified glass sampling apparatus on delivered dose uniformity of fluticasone propionate (FP) dry powder inhaler (DPI). FP DPI was fabricated by spray drying technique using engineered mannitol microparticles (EMP) with different force controlling agents, i.e., leucine and magnesium stearate. Additionally, commercially available two DPI inhaler devices namely Handihaler® and Breezhaler® were used to aerosolize the FP blends. Spherical smooth surface of EMP showed good powder flow properties and acceptable percentage content uniformity (> 95%). Amounts of FP deposited in cascade assembly using USP-modified IP with the Breezhaler® device was significantly higher (1.32-fold) as compared with the Handihaler® device. Moreover, USP-modified IP showed better deposition as compared with USP IP. Additionally, both inhaler devices showed a satisfactory delivered dose (> 105%) for FP using modified glass sampling apparatus at a flow rate of 60 L/min for 2 s. It was interesting to note that not only formulation properties but also IP geometry and device resistance have significant impact on DPI deposition pattern. This study is a first detailed account of aerodynamic performance of FP using USP-modified IP and USP-modified glass sampling apparatus. Thus, it can be of potential importance for both the academic and industry perspective.Keywords
This publication has 26 references indexed in Scilit:
- Assessing Aerosol Performance of a Dry Powder Carrier Formulation with Increasing Doses Using a Novel InhalerAAPS PharmSciTech, 2019
- Novel Inhalable Ciprofloxacin Dry Powders for Bronchiectasis Therapy: Mannitol–Silk Fibroin Binary Microparticles with High-Payload and Improved Aerosolized PropertiesAAPS PharmSciTech, 2019
- Phytoconstituent based dry powder inhalers as biomedicine for the management of pulmonary diseasesBiomedicine & Pharmacotherapy, 2018
- Understanding the Impacts of Surface Compositions on the In-Vitro Dissolution and Aerosolization of Co-Spray-Dried Composite Powder Formulations for InhalationPharmaceutical Research, 2018
- Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and futureArtificial Cells, Nanomedicine, and Biotechnology, 2018
- Imagine the Superiority of Dry Powder Inhalers from Carrier EngineeringJournal of Drug Delivery, 2018
- Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based devicePharmaceutical Development and Technology, 2017
- Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery SystemsJournal of Drug Delivery, 2016
- De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation ProductsThe AAPS Journal, 2015
- Overcoming the Undesirable Properties of dry-powder Inhalers With Novel Engineered Mannitol ParticlesTherapeutic Delivery, 2013